Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;85(7):e70009.
doi: 10.1002/ddr.70009.

Molecular docking, DFT and antiproliferative properties of 4-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine as potent anticancer agent with CDK2 and PIM1 inhibition potency

Faizah A Binjubair  1 , Basma S Almansour  1 , Noha I Ziedan  2 , Alaa A-M Abdel-Aziz  1 , Sara T Al-Rashood  1 , Mohamed K Elgohary  3 , Mahmoud S Elkotamy  3 , Hatem A Abdel-Aziz  4   5
Affiliations

Molecular docking, DFT and antiproliferative properties of 4-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine as potent anticancer agent with CDK2 and PIM1 inhibition potency

Faizah A Binjubair et al. Drug Dev Res. 2024 Nov.

Abstract

Due to the limited effeteness and safety concerns associated with current cancer treatments, there is a pressing need to develop novel therapeutic agents. 4-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine (3) was synthesized and Initially screened on 59 cancer cell lines showed promising anticancer activity, so, it was chosen for a 5-dose experiment by the NCI/USA. The GI50 values ranged from 1.04 to 8.02 μM on the entire nine panels (57 cell lines), with a GI50 of 2.70 μM for (MG-MID) panel, indicating an encouraging action. To further explore the molecular attributes of compound 3, we optimized its structure using DFT with the B3LYP/6-31 + + G(d,p) basis set. We have considered vibrational analysis, bond lengths and angles, FMOs, and MEP for the structure. Additionally, pharmacokinetic assessments were conducted using various in-silico platforms to evaluate the compound safety. A molecular modeling study created a kinase profile on 44 different kinases. This allowed us to study our compound's binding affinity to these kinases and compare it to the co-crystallized one. Our findings revealed compound 3 exhibited better binding for half of the tested kinases, suggesting its potential as a multi-kinase inhibitor. To further validate our computational results, we tested compound 3 for its inhibitory effects on CDK2 and PIM1. Compound 3 exhibited an IC50 of 0.30 µM for CDK2 inhibition, making it five times less active than Roscovitine, which has an IC50 of 0.06 µM. However, compound 3 demonstrated slightly better inhibition of PIM1 compared to Staurosporine. These findings suggest that compound 3 is a promising anticancer agent with the potential for further development into a highly active compound.

Keywords: Anticancer; CDK2; DFT; Molecular docking; PIM1; Pyrazolo[3,4‐b]pyridine.

PubMed Disclaimer

References

REFERENCES

    1. Abo Elmaaty, A., Eldehna, W., Khattab, M., Kutkat, O., Alnajjar, R., El‐Taweel, A., Al‐Rashood, S., Abourehab, M., Binjubair, F., Saleh, M., Belal, A., & Al‐Karmalawy, A. (2022). Anticoagulants as potential SARS‐CoV‐2 M(pro) inhibitors for COVID‐19 patients: in vitro, molecular docking, molecular dynamics, DFT, and Sar studies. International Journal of Molecular Sciences, 23(20), 12235. https://doi.org/10.3390/ijms232012235
    1. Acton, E. M., Narayanan, V. L., Risbood, P. A., Shoemaker, R. H., Vistica, D. T., & Boyd, M. R. (1994). Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. Journal of Medicinal Chemistry, 37(14), 2185–2189.
    1. Almansour, B. S., Binjubair, F. A., Abdel‐Aziz, A. A.‐M., & Al‐Rashood, S. T. (2023). Synthesis and in vitro anticancer activity of novel 4‐Aryl‐3‐(4‐methoxyphenyl)‐1‐phenyl‐1 h‐pyrazolo [3, 4‐b] pyridines arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and/or CDK9. Molecules, 28(17), 6428.
    1. Alshaye, N. A., Elgohary, M. K., Elkotamy, M. S., & Abdel‐Aziz, H. A. (2024). Design, synthesis and biological assessment of N′‐(2‐Oxoindolin‐3‐ylidene)‐6‐methylimidazo[2,1‐b]thiazole‐5‐carbohydrazides as potential Anti‐Proliferative agents toward MCF‐7 breast cancer. Pharmaceuticals, 17(2), 216.
    1. Alshaye, N. A., Elgohary, M. K., Elkotamy, M. S., & Abdel‐Aziz, H. A. (2024a). Design, synthesis and biological assessment of N′‐(2‐Oxoindolin‐3‐ylidene)‐6‐methylimidazo [2, 1‐b] thiazole‐5‐carbohydrazides as potential Anti‐Proliferative agents toward MCF‐7 breast cancer. Pharmaceuticals, 17(2), 216.

MeSH terms

LinkOut - more resources